DarioHealth (DRIO) Competitors

Orchestra BioMed (NASDAQ:OBIO) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends.

Which has stronger earnings and valuation, OBIO or DRIO?

Orchestra BioMed has higher earnings, but lower revenue than DarioHealth. Orchestra BioMed is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$2.89M	41.95	-$49.12M	-$1.78	-1.78
DarioHealth	$28.03M	1.11	-$59.43M	-$0.56	-1.25

Do analysts rate OBIO or DRIO?

Orchestra BioMed currently has a consensus price target of $14.20, suggesting a potential upside of 349.37%. DarioHealth has a consensus price target of $2.00, suggesting a potential upside of 186.74%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, equities analysts clearly believe Orchestra BioMed is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
DarioHealth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Do insiders and institutionals hold more shares of OBIO or DRIO?

53.5% of Orchestra BioMed shares are held by institutional investors. Comparatively, 33.4% of DarioHealth shares are held by institutional investors. 8.1% of Orchestra BioMed shares are held by company insiders. Comparatively, 11.2% of DarioHealth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has more volatility and risk, OBIO or DRIO?

Orchestra BioMed has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, DarioHealth has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.

Does the MarketBeat Community favor OBIO or DRIO?

DarioHealth received 219 more outperform votes than Orchestra BioMed when rated by MarketBeat users. However, 100.00% of users gave Orchestra BioMed an outperform vote while only 66.85% of users gave DarioHealth an outperform vote.

Company	Underperform	Outperform
Orchestra BioMed	Outperform Votes 21 100.00%	Underperform Votes No Votes
DarioHealth	Outperform Votes 240 66.85%	Underperform Votes 119 33.15%

Is OBIO or DRIO more profitable?

DarioHealth has a net margin of -205.62% compared to Orchestra BioMed's net margin of -2,179.33%. DarioHealth's return on equity of -72.16% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-2,179.33%	-107.04%	-70.88%
DarioHealth	-205.62%	-72.16%	-40.74%

Does the media favor OBIO or DRIO?

In the previous week, DarioHealth had 1 more articles in the media than Orchestra BioMed. MarketBeat recorded 2 mentions for DarioHealth and 1 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 1.89 beat DarioHealth's score of 0.93 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Overall Sentiment
Orchestra BioMed	Very Positive
DarioHealth	Positive

Summary

DarioHealth beats Orchestra BioMed on 10 of the 19 factors compared between the two stocks.